{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T15:00:11Z","timestamp":1773673211777,"version":"3.50.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,16]],"date-time":"2021-10-16T00:00:00Z","timestamp":1634342400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,16]],"date-time":"2021-10-16T00:00:00Z","timestamp":1634342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Clin Immunol"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:title>Abstract\n<\/jats:title><jats:p>Unconditioned hematopoietic stem cell transplantation (HSCT) is the recommended treatment for patients with adenosine deaminase (ADA)-deficient severe combined immunodeficiency with an HLA-matched sibling donor (MSD) or family donor (MFD). Improved overall survival (OS) has been reported compared to the use of unrelated donors, and previous studies have demonstrated that adequate cellular and humoral immune recovery can be achieved even in the absence of conditioning. Detailed insight of the long-term outcome is still limited. We aim to address this by studying a large single-center cohort of 28 adenosine deaminase-deficient patients who underwent a total of 31 HSCT procedures, of which more than half were unconditioned. We report an OS of 85.7% and event-free survival of 71% for the entire cohort, with no statistically significant differences after procedures using related or unrelated HLA-matched donors. We find that donor engraftment in the myeloid compartment is significantly diminished in unconditioned procedures, which typically use a MSD or MFD. This is associated with poor metabolic correction and more frequent failure to discontinue immunoglobulin replacement therapy. Approximately one in four patients receiving an unconditioned procedure required a second procedure, whereas the use of reduced intensity conditioning (RIC) prior to allogeneic transplantation improves the long-term outcome by achieving better myeloid engraftment, humoral immune recovery, and metabolic correction. Further longitudinal studies are needed to optimize future management and guidelines, but our findings support a potential role for the routine use of RIC in most ADA-deficient patients receiving an HLA-identical hematopoietic stem cell transplant, even when a MSD or MFD is available.<\/jats:p>","DOI":"10.1007\/s10875-021-01145-w","type":"journal-article","created":{"date-parts":[[2021,10,16]],"date-time":"2021-10-16T13:32:35Z","timestamp":1634391155000},"page":"94-107","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Long-Term Immune Recovery After Hematopoietic Stem Cell Transplantation for ADA Deficiency: a Single-Center Experience"],"prefix":"10.1007","volume":"42","author":[{"given":"Alexandra Y.","family":"Kreins","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena F.","family":"Velasco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai-Ning","family":"Cheong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanchan","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Veys","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Austen","family":"Worth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. Bobby","family":"Gaspar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2626-5037","authenticated-orcid":false,"given":"Claire","family":"Booth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,16]]},"reference":[{"issue":"2","key":"1145_CR1","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.iac.2010.01.002","volume":"30","author":"HB Gaspar","year":"2010","unstructured":"Gaspar HB. Bone marrow transplantation and alternatives for adenosine deaminase deficiency. Immunol Allergy Clin North Am. 2010;30(2):221\u201336.","journal-title":"Immunol Allergy Clin North Am"},{"issue":"1","key":"1145_CR2","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13023-018-0807-5","volume":"13","author":"AM Flinn","year":"2018","unstructured":"Flinn AM, Gennery AR. Adenosine deaminase deficiency: a review. Orphanet J Rare Dis. 2018;13(1):65.","journal-title":"Orphanet J Rare Dis"},{"issue":"7","key":"1145_CR3","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1007\/s10875-017-0433-3","volume":"37","author":"KL Bradford","year":"2017","unstructured":"Bradford KL, et al. Adenosine deaminase (ADA)-deficient severe combined immune deficiency (SCID): molecular pathogenesis and clinical manifestations. J Clin Immunol. 2017;37(7):626\u201337.","journal-title":"J Clin Immunol"},{"issue":"3","key":"1145_CR4","first-page":"647","volume":"26","author":"A Adams","year":"1976","unstructured":"Adams A, Harkness RA. Adenosine deaminase activity in thymus and other human tissues. Clin Exp Immunol. 1976;26(3):647\u20139.","journal-title":"Clin Exp Immunol"},{"issue":"18","key":"1145_CR5","doi-asserted-by":"publisher","first-page":"5448","DOI":"10.1016\/S0021-9258(17)33080-6","volume":"251","author":"MB Van der Weyden","year":"1976","unstructured":"Van der Weyden MB, Kelley WN. Human adenosine deaminase Distribution and properties. J Biol Chem. 1976;251(18):5448\u201356.","journal-title":"J Biol Chem"},{"issue":"12","key":"1145_CR6","doi-asserted-by":"publisher","first-page":"5677","DOI":"10.1073\/pnas.74.12.5677","volume":"74","author":"DA Carson","year":"1977","unstructured":"Carson DA, Kaye J, Seegmiller JE. Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: possible role of nucleoside kinase(s). Proc Natl Acad Sci U S A. 1977;74(12):5677\u201381.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"1145_CR7","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/0387-7604(96)00014-9","volume":"18","author":"C Tanaka","year":"1996","unstructured":"Tanaka C, et al. Sensorineural deafness in siblings with adenosine deaminase deficiency. Brain Dev. 1996;18(4):304\u20136.","journal-title":"Brain Dev"},{"issue":"2","key":"1145_CR8","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.jpeds.2003.10.055","volume":"144","author":"W Albuquerque","year":"2004","unstructured":"Albuquerque W, Gaspar HB. Bilateral sensorineural deafness in adenosine deaminase-deficient severe combined immunodeficiency. J Pediatr. 2004;144(2):278\u201380.","journal-title":"J Pediatr"},{"issue":"3","key":"1145_CR9","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s10875-012-9658-3","volume":"32","author":"C Booth","year":"2012","unstructured":"Booth C, et al. Non-infectious lung disease in patients with adenosine deaminase deficient severe combined immunodeficiency. J Clin Immunol. 2012;32(3):449\u201353.","journal-title":"J Clin Immunol"},{"issue":"6","key":"1145_CR10","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1016\/j.jaci.2012.02.003","volume":"129","author":"E Grunebaum","year":"2012","unstructured":"Grunebaum E, Cutz E, Roifman CM. Pulmonary alveolar proteinosis in patients with adenosine deaminase deficiency. J Allergy Clin Immunol. 2012;129(6):1588\u201393.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"1145_CR11","first-page":"115","volume":"12","author":"I Kaitila","year":"1976","unstructured":"Kaitila I, et al. Chondroosseous histopathology in adenosine deaminase deficient combined immunodeficiency disease. Birth Defects Orig Artic Ser. 1976;12(6):115\u201321.","journal-title":"Birth Defects Orig Artic Ser"},{"issue":"1","key":"1145_CR12","first-page":"157","volume":"120","author":"H Ratech","year":"1985","unstructured":"Ratech H, et al. Pathologic findings in adenosine deaminase-deficient severe combined immunodeficiency. I. Kidney, adrenal, and chondro-osseous tissue alterations. Am J Pathol. 1985;120(1):157\u201369.","journal-title":"Am J Pathol"},{"issue":"5","key":"1145_CR13","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s00247-012-2564-2","volume":"43","author":"D Manson","year":"2013","unstructured":"Manson D, et al. Characteristic scapular and rib changes on chest radiographs of children with ADA-deficiency SCIDS in the first year of life. Pediatr Radiol. 2013;43(5):589\u201392.","journal-title":"Pediatr Radiol"},{"issue":"2","key":"1145_CR14","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s10875-019-00733-1","volume":"40","author":"MV Verhagen","year":"2020","unstructured":"Verhagen MV, et al. Chest radiographs for distinguishing ADA-SCID from other forms of SCID. J Clin Immunol. 2020;40(2):259\u201366.","journal-title":"J Clin Immunol"},{"issue":"4","key":"1145_CR15","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1007\/s10875-020-00777-8","volume":"40","author":"R Pajno","year":"2020","unstructured":"Pajno R, et al. Urogenital abnormalities in adenosine deaminase deficiency. J Clin Immunol. 2020;40(4):610\u20138.","journal-title":"J Clin Immunol"},{"issue":"21","key":"1145_CR16","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1056\/NEJM199605233342104","volume":"334","author":"ME Bollinger","year":"1996","unstructured":"Bollinger ME, et al. Brief report: hepatic dysfunction as a complication of adenosine deaminase deficiency. N Engl J Med. 1996;334(21):1367\u201371.","journal-title":"N Engl J Med"},{"issue":"1","key":"1145_CR17","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1067\/mpd.2001.115023","volume":"139","author":"MH Rogers","year":"2001","unstructured":"Rogers MH, et al. Cognitive and behavioral abnormalities in adenosine deaminase deficient severe combined immunodeficiency. J Pediatr. 2001;139(1):44\u201350.","journal-title":"J Pediatr"},{"issue":"9","key":"1145_CR18","doi-asserted-by":"publisher","first-page":"3907","DOI":"10.1182\/blood-2008-04-151332","volume":"112","author":"P Titman","year":"2008","unstructured":"Titman P, et al. Cognitive and behavioral abnormalities in children after hematopoietic stem cell transplantation for severe congenital immunodeficiencies. Blood. 2008;112(9):3907\u201313.","journal-title":"Blood"},{"issue":"2","key":"1145_CR19","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.clim.2006.12.009","volume":"123","author":"C Booth","year":"2007","unstructured":"Booth C, et al. Management options for adenosine deaminase deficiency; proceedings of the EBMT satellite workshop (Hamburg, March 2006). Clin Immunol. 2007;123(2):139\u201347.","journal-title":"Clin Immunol"},{"issue":"3","key":"1145_CR20","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.jaci.2018.08.024","volume":"143","author":"DB Kohn","year":"2019","unstructured":"Kohn DB, et al. Consensus approach for the management of severe combined immune deficiency caused by adenosine deaminase deficiency. J Allergy Clin Immunol. 2019;143(3):852\u201363.","journal-title":"J Allergy Clin Immunol"},{"issue":"17","key":"1145_CR21","doi-asserted-by":"publisher","first-page":"3615","DOI":"10.1182\/blood-2011-12-396879","volume":"120","author":"A Hassan","year":"2012","unstructured":"Hassan A, et al. Outcome of hematopoietic stem cell transplantation for adenosine deaminase-deficient severe combined immunodeficiency. Blood. 2012;120(17):3615\u201324 quiz 3626.","journal-title":"Blood"},{"key":"1145_CR22","first-page":"349","volume":"3","author":"C Booth","year":"2009","unstructured":"Booth C, Gaspar HB. Pegademase bovine (PEG-ADA) for the treatment of infants and children with severe combined immunodeficiency (SCID). Biologics. 2009;3:349\u201358.","journal-title":"Biologics"},{"issue":"97","key":"1145_CR23","doi-asserted-by":"publisher","first-page":"97ra80","DOI":"10.1126\/scitranslmed.3002716","volume":"3","author":"HB Gaspar","year":"2011","unstructured":"Gaspar HB, et al. Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction. Sci Transl Med. 2011;3(97):97ra80.","journal-title":"Sci Transl Med"},{"issue":"5","key":"1145_CR24","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1056\/NEJMoa0805817","volume":"360","author":"A Aiuti","year":"2009","unstructured":"Aiuti A, et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med. 2009;360(5):447\u201358.","journal-title":"N Engl J Med"},{"issue":"5","key":"1145_CR25","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1172\/JCI90367","volume":"127","author":"KL Shaw","year":"2017","unstructured":"Shaw KL, et al. Clinical efficacy of gene-modified stem cells in adenosine deaminase-deficient immunodeficiency. J Clin Invest. 2017;127(5):1689\u201399.","journal-title":"J Clin Invest"},{"issue":"18","key":"1145_CR26","doi-asserted-by":"publisher","first-page":"3635","DOI":"10.1182\/blood-2012-02-400937","volume":"120","author":"F Candotti","year":"2012","unstructured":"Candotti F, et al. Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans. Blood. 2012;120(18):3635\u201346.","journal-title":"Blood"},{"issue":"8","key":"1145_CR27","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1182\/blood-2006-07-034678","volume":"109","author":"M Honig","year":"2007","unstructured":"Honig M, et al. Patients with adenosine deaminase deficiency surviving after hematopoietic stem cell transplantation are at high risk of CNS complications. Blood. 2007;109(8):3595\u2013602.","journal-title":"Blood"},{"issue":"7","key":"1145_CR28","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1007\/s10875-015-0191-z","volume":"35","author":"R Baffelli","year":"2015","unstructured":"Baffelli R, et al. Diagnosis, treatment and long-term follow up of patients with ADA deficiency: a single-center experience. J Clin Immunol. 2015;35(7):624\u201337.","journal-title":"J Clin Immunol"},{"issue":"6","key":"1145_CR29","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1007\/s10875-017-0421-7","volume":"37","author":"O Scott","year":"2017","unstructured":"Scott O, et al. Long-term outcome of adenosine deaminase-deficient patients-a single-center experience. J Clin Immunol. 2017;37(6):582\u201391.","journal-title":"J Clin Immunol"},{"issue":"4","key":"1145_CR30","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1007\/s10875-018-0496-9","volume":"38","author":"D Cagdas","year":"2018","unstructured":"Cagdas D, et al. ADA deficiency: evaluation of the clinical and laboratory features and the outcome. J Clin Immunol. 2018;38(4):484\u201393.","journal-title":"J Clin Immunol"},{"issue":"5","key":"1145_CR31","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1056\/NEJMoa1401177","volume":"371","author":"SY Pai","year":"2014","unstructured":"Pai SY, et al. Transplantation outcomes for severe combined immunodeficiency, 2000\u20132009. N Engl J Med. 2014;371(5):434\u201346.","journal-title":"N Engl J Med"},{"issue":"8","key":"1145_CR32","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1007\/s10875-020-00857-9","volume":"40","author":"CY Kuo","year":"2020","unstructured":"Kuo CY, et al. Adenosine deaminase (ADA)-deficient severe combined immune deficiency (SCID) in the US immunodeficiency network (USIDNet) registry. J Clin Immunol. 2020;40(8):1124\u201331.","journal-title":"J Clin Immunol"},{"issue":"1","key":"1145_CR33","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/imr.12729","volume":"287","author":"JM Puck","year":"2019","unstructured":"Puck JM. Newborn screening for severe combined immunodeficiency and T-cell lymphopenia. Immunol Rev. 2019;287(1):241\u201352.","journal-title":"Immunol Rev"},{"issue":"25","key":"1145_CR34","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.1182\/blood-2017-05-781849","volume":"130","author":"J Heimall","year":"2017","unstructured":"Heimall J, et al. Immune reconstitution and survival of 100 SCID patients post-hematopoietic cell transplant: a PIDTC natural history study. Blood. 2017;130(25):2718\u201327.","journal-title":"Blood"},{"issue":"2\u20133","key":"1145_CR35","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1007\/s12026-019-09081-z","volume":"67","author":"U Manor","year":"2019","unstructured":"Manor U, et al. Immune reconstitution after HSCT in SCID-a cohort of conditioned and unconditioned patients. Immunol Res. 2019;67(2\u20133):166\u201375.","journal-title":"Immunol Res"},{"issue":"9","key":"1145_CR36","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1016\/j.bbmt.2020.06.004","volume":"26","author":"CF Contreras","year":"2020","unstructured":"Contreras CF, et al. Reduced toxicity conditioning for nonmalignant hematopoietic cell transplants. Biol Blood Marrow Transplant. 2020;26(9):1646\u201354.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"1145_CR37","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.3324\/haematol.2010.025098","volume":"95","author":"C Cancrini","year":"2010","unstructured":"Cancrini C, et al. Role of reduced intensity conditioning in T-cell and B-cell immune reconstitution after HLA-identical bone marrow transplantation in ADA-SCID. Haematologica. 2010;95(10):1778\u201382.","journal-title":"Haematologica"},{"issue":"1","key":"1145_CR38","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1182\/blood-2016-01-688226","volume":"128","author":"MP Cicalese","year":"2016","unstructured":"Cicalese MP, et al. Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency. Blood. 2016;128(1):45\u201354.","journal-title":"Blood"},{"issue":"6","key":"1145_CR39","doi-asserted-by":"publisher","first-page":"737","DOI":"10.15252\/emmm.201707573","volume":"9","author":"A Aiuti","year":"2017","unstructured":"Aiuti A, Roncarolo MG, Naldini L. Gene therapy for ADA-SCID, the first marketing approval of an ex vivo gene therapy in Europe: paving the road for the next generation of advanced therapy medicinal products. EMBO Mol Med. 2017;9(6):737\u201340.","journal-title":"EMBO Mol Med"},{"issue":"5577","key":"1145_CR40","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1126\/science.1070104","volume":"296","author":"A Aiuti","year":"2002","unstructured":"Aiuti A, et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science. 2002;296(5577):2410\u20133.","journal-title":"Science"},{"issue":"10","key":"1145_CR41","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/j.bbmt.2020.07.004","volume":"26","author":"KL Bradford","year":"2020","unstructured":"Bradford KL, et al. Busulfan pharmacokinetics in adenosine deaminase-deficient severe combined immunodeficiency gene therapy. Biol Blood Marrow Transplant. 2020;26(10):1819\u201327.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"1145_CR42","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.ymthe.2017.12.022","volume":"26","author":"MP Cicalese","year":"2018","unstructured":"Cicalese MP, et al. Gene therapy for adenosine deaminase deficiency: a comprehensive evaluation of short- and medium-term safety. Mol Ther. 2018;26(3):917\u201331.","journal-title":"Mol Ther"},{"key":"1145_CR43","unstructured":"therapeutics, O., https:\/\/ir.orchard-tx.com\/index.php\/news-releases\/news-release-details\/orchard-statement-strimvelisr-gammaretroviral-vector-based-gene."},{"issue":"21","key":"1145_CR44","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1056\/NEJMoa2027675","volume":"384","author":"DB Kohn","year":"2021","unstructured":"Kohn DB, et al. Autologous ex vivo lentiviral gene therapy for adenosine deaminase deficiency. N Engl J Med. 2021;384(21):2002\u201313.","journal-title":"N Engl J Med"},{"issue":"5","key":"1145_CR45","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.ymthe.2017.03.018","volume":"25","author":"AJ Thrasher","year":"2017","unstructured":"Thrasher AJ, Williams DA. Evolving gene therapy in primary immunodeficiency. Mol Ther. 2017;25(5):1132\u201341.","journal-title":"Mol Ther"}],"container-title":["Journal of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-021-01145-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10875-021-01145-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-021-01145-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T16:19:06Z","timestamp":1666887546000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10875-021-01145-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,16]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["1145"],"URL":"https:\/\/doi.org\/10.1007\/s10875-021-01145-w","relation":{},"ISSN":["0271-9142","1573-2592"],"issn-type":[{"value":"0271-9142","type":"print"},{"value":"1573-2592","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,16]]},"assertion":[{"value":"2 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"The parents\/guardians provided informed consent for data use under the ESID\/EBMT transplant registry consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent\/Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"CB has received educational honoraria from GSK and Orchard Therapeutics related to ADA-SCID. HBG is an employee of Orchard Therapeutics and holds equity in the company.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}